Clinical trials: Schizophrenia Disorder
Schizophrenia, Drug Abuse
A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse
The prevalence estimates for specific mental disorders and illicit drugs have been separately reported in U.S. government surveys.
- Conditions
- Schizophrenia, Drug Abuse, Anxiety Disorder, Bipolar Disorder
- Trial name
- NCT02476877
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Advanced Clinical Laboratory Solutions, Inc.
Schizophrenia
Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.
- Trial name
- NCT00954122
- Testing
- Quetiapine XR (Seroquel XR)
- Where
- 2 sites in Malaysia
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Sleep Initiation and Maintenance Disorders
A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients
A multicenter, randomized, double-blind, triple-dummy, group-comparison study using placebo and nitrazepam as a comparative drug.
- Trial name
- NCT00374777
- Testing
- zolpidem MR, nitrazepam
- Where
- 6 sites in Japan
- Volunteers
- 450 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia
A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone
The purpose of this study is to evaluate the effects of an organic cation transporter inhibitor, trimethoprim, on the pharmacokinetics of orally administered ER OROS paliperidone and to assess the safety and tolerability of the…
- Trial name
- NCT00892541
- Testing
- ER OROS paliperidone
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization…
- Trial name
- FIRST (NCT02600741)
- Testing
- Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate
- Where
- 34 sites in United States
- Volunteers
- 296 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia
Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults
This study is a multi-site, double-blind, randomized, controlled clinical trial to assess the safety and effectiveness of plasticity-based, adaptive, computerized-based cognitive remediation treatment versus a computer-based…
- Trial name
- e-CAeSAR (NCT01422902)
- Testing
- Plasticity-based Cognitive Training, Non-plasticity-based Training
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Posit Science Corporation
Schizophrenia
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
This randomized, double-blinded, placebo-controlled study will investigate the safety, tolerability, and pharmacokinetics of multiple doses of RO5545965 administered orally to psychiatrically stable patients with schizophrenia…
- Trial name
- NCT02019329
- Testing
- RO5545965, risperidone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Psychotic Disorders
Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the effectiveness and safety of long-acting risperidone given as a once monthly injection to adult patients with schizophrenia or schizoaffective disorder.
- Trial name
- NCT00236353
- Testing
- risperidone
- Volunteers
- 86 people
- Sponsor
- Janssen, LP
Schizophrenia
Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants
The purpose of this study is to evaluate improvement and efficacy of paliperidone extended-release for subjective well-being and drug attitudes of participants, when switching from oral antipsychotics in participants with…
- Trial name
- Power (NCT00784238)
- Testing
- Paliperidone
- Where
- 11 sites in South Korea
- Volunteers
- 289 people
- Sponsor
- Janssen Korea, Ltd., Korea
Metabolic Syndrome, Schizophrenia
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole…
- Trial name
- NCT00508157
- Testing
- Aripiprazole, Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
- Where
- 30 sites in Belgium, Czechia and 7 more
- Volunteers
- 125 people
- Sponsor
- Bristol-Myers Squibb
SCHIZOPHRENIA 1 (Disorder)
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia
This is a Phase 2b, randomized, double-blind, parallel-group, active-controlled and placebo-controlled, multicenter inpatient study to examine the efficacy and safety of HS-10380 in adult Participants who are acutely psychotic…
- Trial name
- NCT07550387
- Testing
- HS-10380 Low Dose, HS-10380 Medium dose, HS-10380 High Dose
- Where
- China
- Volunteers
- 363 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Schizophrenia
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in patients with chronic schizophrenia that are not responding adequately to their current antipsychotic medication (aripiprazole or…
- Trial name
- NCT02624167
- Testing
- NW-3509A
- Where
- 5 sites in United States, India
- Volunteers
- 90 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia
This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.
- Trial name
- NCT01903837
- Testing
- Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose)
- Where
- 61 sites in United States, Bulgaria and 1 more
- Volunteers
- 347 people
- Sponsor
- Alkermes, Inc.
Schizophrenia Disorder
A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia
This study is a prospective, observational, single-arm, open-label, multicenter, real-world study conducted in Chinese adult participants with schizophrenia who meet the International Classification of Diseases (ICD)-10…
- Trial name
- NCT07802132
- Testing
- Xanomeline and trospium chloride (KarXT)
- Volunteers
- 250 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
The purpose of this study is to prove safety and efficacy of aripiprazole.
- Trial name
- NCT00304655
- Testing
- Aripiprazole
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients
An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.
- Trial name
- NCT01086748
- Testing
- Risperidone, LY2140023
- Where
- 28 sites in United States, Croatia and 1 more
- Volunteers
- 1,134 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
This study evaluates PERSERIS at a higher dose than what has been administered in previous clinical trials. Subjects with stable schizophrenia on a dose of 5-6 mg oral risperidone will be switched to PERSERIS at the higher dose…
- Trial name
- NCT03978832
- Testing
- PERSERIS, Risperidone
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Indivior Inc.
Schizophrenia
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
- Trial name
- NCT07288333
- Testing
- NBI-1117570
- Where
- 6 sites in Bulgaria, Romania and 1 more
- Volunteers
- 120 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with…
- Trial name
- NCT02203838
- Testing
- RBP-7000
- Where
- 48 sites in United States
- Volunteers
- 500 people
- Sponsor
- Indivior Inc.
Schizophrenia
SOLIACS: Solian Solution in the Acute Setting
During this study the efficacy and safety profile will be evaluated of the use of amisulpride in the form of a solution in schizophrenic patients with an acute episode.
- Trial name
- NCT00245674
- Testing
- amisulpride
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.